Data as of Mar 10
| -0.33 / -0.95%|
The 7 analysts offering 12-month price forecasts for Theravance Inc have a median target of 47.00, with a high estimate of 52.00 and a low estimate of 13.00. The median estimate represents a +36.11% increase from the last price of 34.53.
The current consensus among 8 polled investment analysts is to Buy stock in Theravance Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.